Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04149574 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)(CheckMate 7G8) | terminated | Phase 3 | 13 | Bristol-Myers SquibbINDUSTRY | 16 | Sep 16, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 |
| clinicaltrials |
| NCT04892342 | Study of ESG401 in Adults With Solid Tumors | completed | Phase 1 / Phase 2 | 156 | Shanghai Escugen Biotechnology Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05739071 | JING SI HERBAL TEA and Urinary Tract Symptoms in Bladder Cancer | enrolling by invitation | N/A | 100 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06351904 | A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy | recruiting | Phase 1 | 72 | Ractigen Therapeutics.OTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07165236 | Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor | recruiting | — | 42 | Osijek University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT00082706 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT04887831 | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab(PRESERVE3) | terminated | Phase 2 | 92 | G1 Therapeutics, Inc.INDUSTRY | 5 | Sep 8, 2025 | clinicaltrials |
| NCT06571708 | Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)(NeoSTOP-IT) | recruiting | Phase 2 | 36 | Columbia UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05879653 | Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD) | recruiting | Phase 2 | 30 | Kyoto University HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT03232541 | The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting | completed | N/A | 198 | Västernorrland County Council, SwedenOTHER_GOV | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07140588 | Pilot Study of a New Nerve Grafting Method During Bladder Cancer Surgery to Help Preserve Erections.(NR-RC) | not yet recruiting | N/A | 10 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT03039413 | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06181266 | A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer(PARADIGM-1) | active not recruiting | Phase 1 | 22 | Prokarium LtdINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT04936230 | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07111364 | Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study(BCA-AI-US) | recruiting | — | 400 | Peking University First HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07125924 | Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer | not yet recruiting | N/A | 54 | National Cancer Center, KoreaOTHER_GOV | 1 | Aug 15, 2025 | clinicaltrials |
| NCT04442724 | Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy(FMBRT) | recruiting | N/A | 60 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05111639 | Decision Making for Urinary Diversion in Patients With Bladder Cancer | completed | — | 52 | University of Colorado, DenverOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07122414 | A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 80 | Suzhou Forlong Biotechnology Co., LtdINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06364956 | Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 36 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04825834 | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)(DELFI-L101) | completed | — | 2,992 | Delfi Diagnostics Inc.INDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT04570410 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | completed | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05123625 | Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC(PLND-Less) | recruiting | N/A | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | terminated | Phase 2 | 4 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07091565 | Supporting Sexual Recovery in Women With Bladder Cancer(SPARC) | enrolling by invitation | — | 60 | King's College LondonOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06691776 | Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)(FASCINATE) | recruiting | N/A | 100 | The Netherlands Cancer InstituteOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04532606 | Impact of Remimazolam on Prognosis After Bladder Cancer Surgery | recruiting | Phase 4 | 1,128 | Peking University First HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06537154 | NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment(NEO-BLAST) | recruiting | Phase 2 / Phase 3 | 688 | Peter BlackOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05524545 | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | completed | Phase 1 | 36 | ALX Oncology Inc.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05151341 | Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors(URODX-FGFR3) | completed | N/A | 190 | Institut de Cancérologie de LorraineOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06880939 | Antarctic Krill Oil Functional Food Mitigates Bladder Cancer Treatment Side Effects | not yet recruiting | N/A | 210 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT07067749 | Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer(TEMPO-MIBC) | recruiting | Phase 3 | 92 | University of Rome Tor VergataOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT02553642 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04574960 | Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)(NAUTICAL) | recruiting | Phase 3 | 14 | University Health Network, TorontoOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06002269 | A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients(BOOST) | completed | N/A | 8 | University of UtahOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07064863 | A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.(BCG-TIME) | not yet recruiting | Phase 1 / Phase 2 | 31 | Queen's UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07053722 | Observational Clinical Study of Patients With Muscle - Invasive Bladder Cancer Undergoing Bladder Preservation Therapy After Neoadjuvant Therapy | not yet recruiting | — | 30 | Peking University First HospitalOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07053735 | An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer | not yet recruiting | Phase 1 | 30 | Peking University First HospitalOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07051083 | Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale(MICS-BC) | recruiting | — | 480 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT02015104 | Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03081858 | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 15 | Lipac Oncology LLCINDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 16, 2025source: clinicaltrials